MFG
ITCI

Merit Financial Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Merit Financial Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,798
Closed -$369K – 1758
2025
Q1 		$369K Buy
2,798
+333
+14% +$41.5K 0.01% 1054
2024
Q4 		$206K Buy
+2,465
New +$203K ﹤0.01% 1088

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Merit Financial Group's ITCI Position: Q2 2025 in Review

Merit Financial Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2,798 shares — an estimated $369K sold.

Merit Financial Group first reported a position in ITCI in Q4 2024 and held it in 2 quarters. The position peaked at $369K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Merit Financial Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Merit Financial Group sold 2,798 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $369K.
  • Merit Financial Group first reported a position in Intra-Cellular Therapies Inc. in Q4 2024 and held it in 2 quarters.
  • Merit Financial Group's Intra-Cellular Therapies Inc. position peaked at $369K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Merit Financial Group's 13F filing for Q2 2025, filed 22 Jul 2025.